본문 바로가기
대메뉴 바로가기
KAIST
Newsletter Vol.25
Receive KAIST news by email!
View
Subscribe
Close
Type your e-mail address here.
Subscribe
Close
KAIST
NEWS
유틸열기
홈페이지 통합검색
-
검색
KOREAN
메뉴 열기
Cell
by recently order
by view order
Prof. Cho Identifies Dynamics of Signal Transportation System in Control of Cell Proliferation
KAIST, Jan. 22, 2009 -- A research team led by Prof. Kwang-Hyun Cho of the Department of Bio and Brain Engineering, KAIST, has identified a hidden mechanism of the dynamic behavior of signal transportation system involved in the control of cell proliferation, university authorities said. The finding is expected to provide a clue to appropriately controlling the pathway of ERK protein which is known to play a significant role in causing and spreading cancer. The research was featured as the cover paper of the latest online edition of the Journal of Cell Science. The Ras-Raf-MEK-ERK pathway (or ERK pathway) is an important signal transduction system involved in the control of cell proliferation, survival and differentiation. However, the dynamic regulation of the pathway by positive- and negative-feedback mechanism, in particular the functional role of Raf kinase inhibitor protein (RKIP) are still incompletely understood. RKIP is a physiological endogenous inhibitor of MEK phosphorylation by Raf kinases, but also participates in a positive-feedback loop in which ERK can inactivate RKIP. "We attempted to unearth the hidden dynamics of these feedback mechanisms and to identify the functional role of RKIP through combined efforts of biochemical experiments and computer simulations based on an experimentally validated mechanical model," Prof. Cho was quoted as saying.
2009.02.03
View 11085
KAIST Opens Cell Bench Research Center
KAIST opened a cell bench research center on the campus on Monday, Nov. 17, as a joint project with Samsung Electric Co. and Samsung Medical Center. On hand at the opening ceremony were about 100 persons from the three organizations, including KAIST President Nam-Pyo Suh, Samsung Electric"s Chief Technology Officer (CTO) Byung-Cheon Koh and Samsung Medical Center Vice President Hyo-Geun Lim. The newly-opened research center will be involved in the development of individually-tailored anti-cancer medicine using bio-inspired cell chips and technologies for clinical applications. Prof. Young-Ho Cho of the Department of Bio and Brain Engineering was named director of the research center. "Top-notch professionals from the electronic industry, academia and the medical community have gathered together to establish this research center. We expect the center will open a new path for the science and technology community and the industry to combine their strengths and develop innovative anti-cancer therapeutics," said KAIST President Nam-Pyo Suh at the opening ceremony. "The development of bio-cell chip technology represents a new challenge for the Samsung Electric which has focused on information technologies thus far. Through cooperation with KAIST and Samsung Medical Center, we expect to be able to develop a simple and efficient cure for cancer patients," commented Samsung Electric CTO Byung-Cheon Koh. The research center will be initially concentrating on the development of cell chips for lung cancer, one of the primary causes of death for Koreans.
2008.11.17
View 14755
President Nam-Pyo Suh Receives Lifetime Achievement Award from SPE
President Nam-Pyo Suh has been selected as a recipient of the Lifetime Achievement Award by the Society of Plastic Engineers (SPE). The SPE is the largest professional organization that promotes polymer-related R&D. The SPE announced that it recognizes President Suh’s many contributions to the field of polymer processing. President Suh established the first university/industry cooperative research program at MIT known as the MIT-Industry Polymer Processing Program, which became a model in establishing similar programs at many other universities by NSF. Among the many new materials, products and manufacturing processes invented by him are: Microcellular plastics, known as MuCell and used commercially worldwide, USM high pressure foam molding technology, electrostatic charge-decay NDE technique for polymeric materials, and foam/straight plastic lamination process (a major industrial product).
2007.04.12
View 12996
Researchers Find Mechanism of Tumor Suppressor Genes
By Kim Tae-gyu. Staff ReporterTHE Korea Times 02-06-2004 Korean scientists continue to break new ground in fighting cancer as domestic researchers examined the mechanism of a gene which can help detect and treat various sorts of cancer. Korea Advanced Institute of Science and Technology (KAIST) Prof. Lim Dae-sik on Thursday said his team uncovered the mechanism of RASSF1A (Ras Association Domain Family 1 A), or tumor suppressor genes, for the first time in the world. The gene was widely considered to play an important role in reducing the proliferation of cancer cells, but its exact function and processes have remained unknown up to now. It is the second cancer-related breakthrough by Koreans in a week after Korea Institute of Science and Technology (KIST) Prof. Chung Hesson unveiled the oral anti-cancer drug. ``Cancer results from the failed management of cell cycles due to things like radiation. After a two-year intensive study, we found out how RASSF1A governs the cell cycle,"" Lim said. Lim added cancer is caused by abnormal cells, which continue to grow and divide out of control unlike normal cells, which die over time. Cancer cells develop into malignant tumors, eventually inflicting damaging effect on the human body. As a result, a lack of the RASSF1A indicates a high possibility of cancer and injection of it into cells is believed to help cure the deadly disease, according to Lim. Dr. Song Min-sup, who took charge of the research, said the findings will especially pave the way for the detection and treatment of lung cancer. ``The dearth of RASSF1A was reported mostly in the case of lung cancer. The new findings will provide insight into the diagnosis and cure of lung cancer from its early stages,"" Song explained. Lung cancer is a very elusive disease because it doesn"t cause symptoms in its infancy. When symptoms do occur, usually it is too late. ``We expect commercial detection kits or drugs for lung cancer in around five years after pre-clinic experimentation and two-phase clinic trials,"" Song expected. Details of the study is available in the scientific journal Nature Cell Biology in its February edition. voc200@koreatimes.co.kr
2004.03.15
View 16321
<<
첫번째페이지
<
이전 페이지
1
2
3
4
5
6
7
8
9
>
다음 페이지
>>
마지막 페이지 9